Home Healthcare Dermatology Drugs Market
dermatology drugs market

Dermatology Drugs Market [(By Therapeutic Area (Atopic Dermatitis, Psoriasis, Acne, Rosacea), By Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), By Approved Treatments (etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), golimumab (Simponi), brodalumab (Siliq), and guselkamab (Tremfya), and By Region]: Market Size & Forecast, 2017 – 2022

  • Published Date: Feb 2018
  • Pages: 75
  • Format: PDF
  • Report ID: PM1106
  • Base Year: 2016
  • Historical Data: 2015-2016

Report Summary

The global dermatology drugs market was valued at USD 20 billion in 2016 and is estimated to grow at a healthy CAGR from 2017 to 2022. The Report covers the dermatology therapeutic area, major indications and its treatment and diagnose patterns. The Report provides the forecast of Dermatology Drugs market globally, by Regions, indications and Drugs level. The Report also brings the understanding of the market opportunities facing this market by focusing on the major drivers of this market.

Dermatology is a diverse specialty encompassing disorders and diseases of the skin, mucous membrane, hair and nails. Diseases in this category include acne, multiple inflammatory dermatoses, skin cancers, autoimmune disease, occupational dermatitis and contact dermatitis. It’s a highly fragmented therapeutic area, under which comes, acne, rosacea, psoriasis, atopic dermatitis, and other disorders.

Out of all dermatological indications, Psoriasis is the largest with several approved biologics and followed by Acne.  Psoriasis affects approximately 8 million patients in the U.S. and roughly 20-30% have moderate to severe psoriasis. Out of them, only 10% of the moderate to severe patients are treated with biologics. Acne is the most commonly treated skin disorders and occurs in adolescents and patients between 15-24 years of age. Despite the size of the market, there is no single best treatment for acne and therefore combinations treatments are often used. Currently, Topical therapies dominate the acne treatment. There remains significant unmet need in the Dermatology drugs market as current treatment options do not offer improved safety, efficacy and tolerability profile often with low patient compliance.

E-pharmacy Market Scope

By Therapeutic Area

By Marketed Therapies

By Approved Treatments

By Region

  • Atopic Dermatitis
  • Psoriasis
  • Acne
  • Rosacea
  • Biologics
  • Oral Drugs
  • Topical Drugs
  • Etanercept (Enbrel)
  • Infliximab (Remicade)
  • Adalimumab (Humira)
  • Ustekinumab (Stelara)
  • Secukinumab (Cosentyx)
  • Ixekizumab (Taltz)
  • Golimumab (Simponi)
  • Brodalumab (Siliq)
  • Guselkamab (Tremfya)
  • North America (U.S., Canada)
  • Europe (Germany, UK, France, Italy, Spain, Belgium, Russia, Netherlands)
  • Asia-Pacific (China, Japan, India, Australia, Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East and Africa (UAE, Saudi Arabia, South Africa)

Know more about this report: request for sample pages

Segment Analysis

Polaris Market Research has provided the forecasts of the global dermatology drugs market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

  • Market analysis of the dermatology drugs market by key indications.
  • Market analysis of the dermatology drugs market by drug class/approved treatments.
  • Market analysis of the dermatology drugs market by regions.
Key Take-Away
Polaris Market Research
Global Dermatology Drugs Market Size & Share - Industry Report, 2022